Luther strengthens Health Care & Life Science practice with new partner

Frankfurt am Main, 02.04.2024 – Luther Rechtsanwaltsgesellschaft is further expanding its Health Care & Life Science practice and is pleased to announce the addition of partner Elisabeth Kohoutek (39) as of 1 April 2024. With her expertise in the pharmaceutical, life science and digital health sectors, Elisabeth Kohoutek will strengthen Luther's Frankfurt team.


Elisabeth Kohoutek comes from King & Spalding and advises clients in the pharmaceutical and healthcare sectors, in particular at the interface between law, technology and science. She has extensive experience in relevant core areas such as pharmaceutical and medical device law, data protection, regulatory compliance, product liability, telemedicine and remote treatment, utilisation of health data and clinical research. Her advice covers the development and market launch of pharmaceuticals, medical devices, innovative digital health products and concepts, the negotiation of complex concepts, negotiating complex contracts and ensuring compliance with applicable laws and pan-European regulations.

The JUVE Handbook of Commercial Law Firms 2023/24 ranks Elisabeth Kohoutek as an "up-and-comer in the healthcare sector". Legal 500 Germany also recommends her for the areas of Industry Focus: Healthcare and Intellectual Property: Competition Law.

At Luther, Elisabeth Kohoutek will strengthen the Antitrust & Regulation service line and the Health Care & Life Science industry group. The full-service law firm advises numerous clients from the highly regulated and constantly changing healthcare sector across all areas of law.

Anne Wegner, Head of Antitrust & Regulation at Luther, is delighted with the new addition: "We are very happy that Elisabeth Kohoutek will enable us to further expand our advisory practice in the life sciences sector – including in the forward-looking area of digital health - and in particular to strengthen our presence at the Frankfurt office."

As co-heads of Luther's Health Care & Life Science industry group, Prof Dr Christian Burholt and Dr Oliver Kairies are also enthusiastic about the strong development: "The addition of Elisabeth Kohoutek – a rising star in the healthcare sector – is another important building block for further deepening and expanding our regulatory expertise in the life science/pharma/medtech sector in particular."